39650-64-1

Basic information

• Product Name: 1H-Benzimidazole-2-butanamine(9CI)
• Synonyms: 1H-Benzimidazole-2-butanamine(9CI);1H-BenziMidazole-2-butanaMine;4-(1H-benzimidazol-2-yl)butan-1-amine
• CAS NO: 39650-64-1
• Molecular Formula: C₁₁H₁₅N₃
• Molecular Weight: 189.26
• Product Categories: BENZIMIDAZOLE
• Mol File: 39650-64-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazole-2-butanamine(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-2-butanamine(9CI)(39650-64-1)
• EPA Substance Registry System: 1H-Benzimidazole-2-butanamine(9CI)(39650-64-1)

Safety Data

• Hazardous Substances Data: 39650-64-1(Hazardous Substances Data)

Usage

Chemical structure

Composed of a benzimidazole ring and a butanamine group.

Application

Used as a building block in the synthesis of various pharmaceuticals.

Target diseases

Specifically developed for antiparasitic, antifungal, and antibacterial agents.

Therapeutic potential

Shown potential as a therapeutic agent for various diseases, including cancer and neurodegenerative disorders.

Additional properties

Studied for its anti-inflammatory and analgesic properties.

Research value

Considered versatile and valuable for medicinal chemistry research.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 2453-51-2 4-(Benzimidazol-2-yl)-butan-1-ol 
• 542-28-9 3,4,5,6-tetrahydro-2H-pyran-2-one 
• 660-88-8 5-aminopentanoic acid 
• 675-20-7 piperidin-2-one 

Relevant articles and documents

Study of the Effect of Substituents of ortho-Phenylenediamines in the Opening of Lactones and Lactams for Access to Benzimidazol-2-yl Alkanols and Benzimidazol-2-yl Alkylamines

Benzimidazoles represent common chemical moieties in bioactive compounds. The synthesis of this heterocycle often involves a condensation of an ortho-phenylenediamine with a carboxylic acid derivative. The observed dialkylation of the starting ortho-phenylenediamine is avoided by opening of lactones or lactams. This strategy can directly yield 1 H-benzimidazoles substituted at the 2-position by a functionalized chain. We present herein a study of the effect of different electron-withdrawing or electron-donating groups at the 4-position of ortho-phenylenediamines on the opening of lactones or lactams to synthesize benzimidazol-2-yl alkanols and benzimidazol-2-yl alkylamines.

A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N -[3-[(Benzimidazol-2-yl)amino]propyl]amides

Malaria continues to be a major global health problem, being particularly devastating in the African population under the age of five. Artemisinin-based combination therapies (ACTs) are the first-line treatment recommended by the WHO to treat Plasmodium falciparum malaria, but clinical resistance against them has already been reported. As a consequence, novel chemotypes are urgently needed. Herein we report a novel, in vivo active, fast-acting antimalarial chemotype based on a benzimidazole core. This discovery is the result of a medicinal chemistry plan focused on improving the developability profile of an antichlamydial chemical class previously reported by our group. (Graph Presented).